Ferrer Internacional
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Loxapine (Adasuve)No recent activity | Phase 3 | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder |
| Phase 2 | Multi-mechanism secondary-prevention polypillSmall molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
26 August 2022Topline resultCNIC-Ferrer polypillPhase 3 SECURE (NCT02596126) met its primary endpoint: polypill reduced major cardiovascular events versus usual care
Financial reports
No financial reports recorded.